Indivior PLC (LON:INDV)‘s stock had its “buy” rating reissued by equities researchers at Numis Securities Ltd in a research note issued to investors on Tuesday, July 11th, reports. They presently have a GBX 490 ($6.46) target price on the specialty pharmaceutical company’s stock. Numis Securities Ltd’s price target indicates a potential upside of 22.26% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on the company. Royal Bank Of Canada cut Indivior PLC to a “sector performer” rating and upped their target price for the stock from GBX 370 ($4.88) to GBX 390 ($5.14) in a research report on Monday, March 13th. Jefferies Group LLC reaffirmed a “buy” rating and set a GBX 490 ($6.46) target price on shares of Indivior PLC in a research report on Thursday, May 4th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 500 ($6.60) target price on shares of Indivior PLC in a research report on Thursday, May 4th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Indivior PLC presently has an average rating of “Buy” and an average target price of GBX 447.50 ($5.90).

Indivior PLC (LON:INDV) traded up 3.03% during mid-day trading on Tuesday, hitting GBX 400.80. 2,098,869 shares of the stock were exchanged. The stock’s market cap is GBX 2.89 billion. Indivior PLC has a 52 week low of GBX 261.30 and a 52 week high of GBX 401.00. The company has a 50 day moving average price of GBX 325.21 and a 200 day moving average price of GBX 327.49.

ILLEGAL ACTIVITY WARNING: “Indivior PLC (INDV) Rating Reiterated by Numis Securities Ltd” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.